Literature DB >> 14648655

New insights into the roles of matrix metalloproteinases in colorectal cancer development and progression.

Matthew F Leeman1, Stephanie Curran, Graeme I Murray.   

Abstract

This review outlines new concepts that are emerging for the functions of matrix metalloproteinases in colorectal cancer development and progression. The two main concepts that will be discussed are the role of matrix metalloproteinases in the early stages of colorectal tumour development and the functional mechanisms by which matrix metalloproteinases contribute to colorectal tumour invasion and metastasis. The matrix metalloproteinases are a group of enzymes, which have been best characterized for their ability to degrade extracellular matrix proteins and thus they have been extensively studied in tumour invasion. It is now becoming recognized that the matrix metalloproteinases have key roles in a variety of biological processes that are distinct from their well-defined role in matrix degradation. This group of enzymes has been shown to interact with a broad range of non-matrix proteins including growth factors and their receptors, mediators of apoptosis, and cell adhesion molecules. The elucidation of novel biological roles for the matrix metalloproteinases also challenges the current predominant concept of matrix metalloproteinases as enzymes only involved in matrix degradation. Recent studies have shown that several matrix metalloproteinases, especially matrilysin (MMP-7), interact with the specific molecular genetic and signalling pathways involved in colorectal cancer development. In particular, matrilysin is activated at an early stage of colorectal tumourigenesis by the beta-catenin signalling pathway. Furthermore, studies are now elucidating specific mechanisms by which individual matrix metalloproteinases, especially membrane-type matrix metalloproteinases, interact with specific cell adhesion molecules and cytoskeletal proteins and thus contribute dynamically to colorectal tumour invasion. Copyright 2003 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14648655     DOI: 10.1002/path.1466

Source DB:  PubMed          Journal:  J Pathol        ISSN: 0022-3417            Impact factor:   7.996


  42 in total

1.  Conference report--extracellular matrix and cancer: revisiting metalloproteinases highlights from the annual meeting of the American Society for Cell Biology; December 13-17, 2003; San Francisco, California.

Authors:  Sara M Mariani
Journal:  MedGenMed       Date:  2004-02-23

2.  Beta-catenin up-regulates the expression of cyclinD1, c-myc and MMP-7 in human pancreatic cancer: relationships with carcinogenesis and metastasis.

Authors:  Yu-Jun Li; Zhi-Min Wei; Yun-Xiao Meng; Xiang-Rui Ji
Journal:  World J Gastroenterol       Date:  2005-04-14       Impact factor: 5.742

3.  Autoantibodies against MMP-7 as a novel diagnostic biomarker in esophageal squamous cell carcinoma.

Authors:  Jing-Hua Zhou; Bin Zhang; Kemp H Kernstine; Li Zhong
Journal:  World J Gastroenterol       Date:  2011-03-14       Impact factor: 5.742

Review 4.  Is there a genetic signature for liver metastasis in colorectal cancer?

Authors:  Cristina Nadal; Joan Maurel; Pere Gascon
Journal:  World J Gastroenterol       Date:  2007-11-28       Impact factor: 5.742

5.  Anomalous pH-dependence of the activity of human matrilysin (matrix metalloproteinase-7) as revealed by nitration and amination of its tyrosine residues.

Authors:  Yuko Muta; Hiroshi Oneda; Kuniyo Inouye
Journal:  Biochem J       Date:  2005-03-01       Impact factor: 3.857

6.  MMP13, Birc2 (cIAP1), and Birc3 (cIAP2), amplified on chromosome 9, collaborate with p53 deficiency in mouse osteosarcoma progression.

Authors:  Ou Ma; Wei-Wen Cai; Lars Zender; Tajhal Dayaram; Jianhe Shen; Alan J Herron; Scott W Lowe; Tsz-Kwong Man; Ching C Lau; Lawrence A Donehower
Journal:  Cancer Res       Date:  2009-03-10       Impact factor: 12.701

7.  Elevated expressions of MMP7, TROP2, and survivin are associated with survival, disease recurrence, and liver metastasis of colon cancer.

Authors:  Y J Fang; Z H Lu; G Q Wang; Z Z Pan; Z W Zhou; J P Yun; M F Zhang; D S Wan
Journal:  Int J Colorectal Dis       Date:  2009-05-07       Impact factor: 2.571

8.  Syndecan-2 functions as a docking receptor for pro-matrix metalloproteinase-7 in human colon cancer cells.

Authors:  Heui-Young Ryu; Jiseon Lee; Sanghwa Yang; Haein Park; Sojoong Choi; Kyeong-Cheon Jung; Seung-Taek Lee; Je-Kyung Seong; Inn-Oc Han; Eok-Soo Oh
Journal:  J Biol Chem       Date:  2009-12-18       Impact factor: 5.157

9.  Expression and intracellular localization of matrix metalloproteinases in intraductal papillary mucinous neoplasms of the pancreas.

Authors:  Urara Tamahashi; Jiro Kumagai; Touichiro Takizawa; Masaki Sekine; Yoshinobu Eishi
Journal:  Virchows Arch       Date:  2008-05-24       Impact factor: 4.064

10.  MMP7 expression regulated by endocrine therapy in ERbeta-positive colon cancer cells.

Authors:  Yu-Jing Fang; Zhi-Zhong Pan; Li-Ren Li; Zhen-Hai Lu; Li-Yi Zhang; De-Sen Wan
Journal:  J Exp Clin Cancer Res       Date:  2009-09-29
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.